A pilot study to evaluate the safety and efficacy of a personalised cancer vaccine in patients with completely resected early stage lung cancer

Dataset includes: demographic data, diagnostic data, and safety data for a pilot study of 6 participants with early stage non small cell lung cancer (NSCLC) to evaluate the safety of a personalised tumour neo-antigen peptide vaccine strategy. The personalised neo-antigen peptide vaccine will comprise of 5 to 10 candidate tumour neo-antigens identified by genome sequencing.